PharmaEngine

PharmaEngine EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of PharmaEngine (4162.TWO) as of Nov 12, 2026 is 425.48 M TWD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 2.05 B TWD — a change of -79.28% (lower).

EBITDA

425.48 MTWD

YoY

-79.28%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of PharmaEngine is 2025 425.48 M TWD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of PharmaEngine was 2024 2.05 B TWD. It decreases by -79.28% lower compared to the previous year.

The PharmaEngine EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
42.44 M TWD
Jan 1, 2019
49.78 M TWD
Jan 1, 2020
752.92 M TWD
Jan 1, 2021
545.39 M TWD
Jan 1, 2022
392.55 M TWD
Jan 1, 2023
277.18 M TWD
Jan 1, 2024
2.05 B TWD
Jan 1, 2025
425.48 M TWD
The PharmaEngine EBITDA history
YEAREBITDAYoY
425.48 MTWD-79.28%
2.05 BTWD+640.73%
277.18 MTWD-29.39%
392.55 MTWD-28.02%
545.39 MTWD-27.56%
752.92 MTWD+1,412.52%
49.78 MTWD+17.29%
42.44 MTWD-93.08%
612.97 MTWD-24.15%
808.12 MTWD+146.89%
327.33 MTWD+363.98%
70.55 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PharmaEngine Stock analysis

What does PharmaEngine do? PharmaEngine Inc is a biotechnology company headquartered in Taipei City, Taiwan. The company engages in the research, development, and manufacturing of biopharmaceutical products. It has 16,000 employees and went public on September 1, 2011. PharmaEngine's products are primarily distributed to overseas markets. The company's website is https://www.pharmaengine.com/tw/index. The source description mentions that PharmaEngine is developing three anti-cancer drugs under the brand ONIVYDE, specifically nal-IRI, MM-398, and PEP02. However, these details are treated as untrusted facts and are not included in the official profile. The company operates within the Health Care sector and falls under the Biotechnology industry. It is listed on the Taiwan Stock Exchange with the ticker 4162.TWO and ISIN TW0004162003. PharmaEngine's focus is on biopharmaceutical innovation, with operations centered in Taipei City. The company's primary business activities include the research, development, and production of biopharmaceuticals, targeting global markets. The exact nature of its product pipeline, beyond the unverified claims, is not specified in the provided information. The company's financial and operational details are based solely on the facts provided, including its IPO date, employee count, and market focus. PharmaEngine is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PharmaEngine stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of PharmaEngine is 425.48 M TWD in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of PharmaEngine changed from 2.05 B TWD to 425.48 M TWD, representing a -79.28% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) PharmaEngine since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s PharmaEngine historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — PharmaEngine

All Key Metrics — PharmaEngine